

# Teslar

Telmisartan

## Composition

**Teslar 20 Tablet:** Each film coated tablet contains Telmisartan USP 20 mg.

**Teslar 40 Tablet:** Each film coated tablet contains Telmisartan USP 40 mg.

**Teslar 80 Tablet:** Each film coated tablet contains Telmisartan USP 80 mg.

## Description

**Teslar** is a preparation of Telmisartan which is a non-peptide angiotensin-II receptor antagonist. Angiotensin-II is formed from angiotensin-I in a reaction catalyzed by angiotensin converting enzyme. Angiotensin-II is the principal agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin-II by selectively blocking the binding of angiotensin-II to the AT<sub>1</sub> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin-II synthesis. Telmisartan has much greater affinity (>3,000 fold) for the AT<sub>1</sub> receptor than for the AT<sub>2</sub> receptor. Because Telmisartan does not inhibit ACE (kininase-II), it does not affect the response to bradykinin. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

## Indications

*Hypertension:* Treatment of essential hypertension in adults.

*Cardiovascular prevention:* Reduction of cardiovascular morbidity in adults with:

- Manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or
- Type 2 diabetes mellitus with documented target organ damage.

## Dosage and Administration

Treatment of hypertension: In case of hypertension usually 40 mg once daily for at least 4 weeks. Increased if necessary up to maximum 80 mg once daily. Blood pressure response is dose related over the range of 20 mg to 80 mg. *Cardiovascular risk reduction:* 40 mg twice daily or 80 mg once daily.

## Contraindications

It is contraindicated in patients with known hypersensitivity of Telmisartan.

## Side Effects

*In hypertensive patients:*

The most common side effects of Telmisartan include sinus pain and congestion (sinusitis), back pain, diarrhoea etc.

*For patients of cardiovascular risk reduction:* The most common side effects of Telmisartan in CV risk reduction include intermittent claudication and skin ulcer.

## Drug Interactions

When certain medicines are taken together, there is a possibility of developing drug interactions. With Telmisartan, drugs such as potassium supplements or potassium sparing diuretics may cause an interaction. When Telmisartan was co-administered with Digoxin, median increases in Digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect. Monitor renal function periodically in patients receiving Telmisartan and NSAID therapy.

## Use in Specific Population

*Use in pregnancy:* Telmisartan is US-FDA pregnancy category D drug. When pregnancy is detected or expected, Telmisartan should be discontinued as soon as possible.

*Use in Lactation:* It is not known whether Telmisartan passes into human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother, the importance of nursing to the infant.

*Hepatic Insufficiency:* Caution should be taken in patients with biliary obstructive disorders or hepatic insufficiency.

*Geriatric patients (>65 years of age):* No overall differences in effectiveness and safety were observed in these patients compared to younger patients.

*Pediatric patients:* Safety and effectiveness in pediatric patients have not been established.

## Overdosage

Limited data are available with regard to overdose in humans. The most likely manifestation of overdose with Telmisartan would be hypotension, dizziness and tachycardia. If overdose occurs, supportive treatment should be given.

## Storage condition

Store below 30°C and dry place, away from light. Store in the original package in order to protect from moisture. Keep out of the reach of children.

## Commercial Pack

**Teslar 20 Tablet:** Each commercial box contains 28 film coated tablets in Alu-Alu blister pack.

**Teslar 40 Tablet:** Each commercial box contains 28 film coated tablets in Alu-Alu blister pack.

**Teslar 80 Tablet:** Each commercial box contains 28 film coated tablets in Alu-Alu blister pack.

Manufactured By

**BEACON**<sup>®</sup>  
Pharmaceuticals PLC  
Bhaluka, Mymensingh, Bangladesh

LF-41301